Skip to Content

Curtis A. Pettaway, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Department of Urology
Unit Number: 1373
Houston, TX 77030
Phone: (713) 792-3250
Fax: (713) 794-4824

Education & Training

Degree-Granting Education

1983 Temple University School of Medicine, Philadelphia, PA, MD, Medicine
1978 Millersville University, Millersville, PA, BA, Biology

Postgraduate Training

7/1991-6/1993 Fellowship in Urologic Oncology, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Isaiah Fidler DVM, PhD, Research Mentor; Andrew C. von Eschenbach, MD, Clinical Mentor
7/1987-6/1991 Urology Residency, Urology, The University of Texas Southwestern Medical School, Dallas, TX, Paul C. Peters, MD
7/1986-6/1987 Surgical Residency, Surgery, Parkland Memorial Hospital, Dallas, TX, William Fry, MD
7/1984-6/1986 Postdoctoral Research Fellow, Internal Medicine, The University of Texas Health Science Center, Dallas, TX, Peter Stastny
7/1983-6/1984 Surgical Residency, Surgery, Parkland Memorial Hospital, Dallas, TX, William Fry, MD

Board Certifications

1/1995 American Board of Urology, Recertification Date: 2/2014


Academic Appointments

Associate Professor, Department of Urology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1999-8/2006
Associate Professor, Department of Cancer Biology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1999-8/2006
Assistant Professor, Department of Cancer Biology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1998-8/1999
Assistant Professor, Department of Urology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1994-8/1998
Faculty Associate, Department of Urology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1993-8/1994

Administrative Appointments/Responsibilities

Medical Director, The University of Texas MD Anderson Cancer Center Prostate Outreach Project, Houston, TX, 2003-present

Other Appointments/Responsibilities

GU Task Force, American Joint Committee on Cancer (AJCC), Chicago, IL, 1/2007-present
REDUCE Steering Committee, GlaxoSmithKline, Durham, NC, 1/2004-2009
Board Member, Walden, Addison, TX, 11/2001-1/2005
2002 Gertrude B. Elion Research Selection Committee, American Association for Cancer Research, Philadelphia, PA, 9/2001
Prostate Cancer Committee, American Cancer Society, Atlanta, GA, 1/1996-present
Prostate Cancer Prevention Trial Data and Safety Monitoring Committee, NCI/SWOG, Bethesda, MD, 1/1996-1/2004
Board of Directors, American Cancer Society, Atlanta, GA, 1/1994-1/1999

Institutional Committee Activities

Member, Division of Cancer Prevention Chair Search Committee, 6/2006-5/2007
Member, Infectious Disease Chair Search Committee, 1/2003-1/2005
Member, Health Disparities Chair Search Committee, 1/2003-1/2005
Co-Chair, Internal Scientific Advisory Committee to Center for Research on Minority Health, 12/2001
Member, Clinical Cancer Prevention Steering Committee, 9/2001
Selection Committee, Faculty Achievement Award, Patient Care, 1/2001
Member, Prostate Cancer Guidelines Committee, 12/2000
Member, Division of Surgery Promotions Committee, 9/2000
Selection Committee, Faculty Achievement Award, Clinical Research, 1/2000
Section Head of Cardiology, Search Committee, 1/2000
Member, Center for Research on Minority Health, Prostate Committee, 1/2000
Judges Panel, Trainee Recognition Day, 1/1999
Member, Faculty Compensation and Retention Committee, 1/1998
Member, Faculty Achievement Award, Cancer Prevention, Selection Committee, 1/1998
Member, Steering Committee on Cancer and Minorities, 1/1998
Medical Advisor, Prostate Cancer Outreach Initiative, 1/1998
Institutional Review Board, Clinical Research Committee, 1/1997-1/2000
Junior Faculty Member, Presidential Search Committee, 1/1995

Honors and Awards

2013 Community Trailblazer Award 2013, One Heritage Society
2008 American Leading Doctors., Black Enterprise Magazine
2006 Citizen of the Year Award, Rho Beta Beta Chapter of Omega Psi Phi Fraternity, Inc.
2004 Certificate of Appreciation, St. Andrews United Methodist Church
2004 Minerva Award for Community Service in Physical and Mental Health, Delta Sigma Theta Sorority Inc., Houston Metropolitan Chapter
2004 Note of Appreciation Award, The Community of Faith Health & Fitness Fair
2000 Harold P. Freeman Award, American Cancer Society Texas Division
1998 Award for Prostate Cancer Education in the African American Community, 100 Black Men of Houston
1997 Achievement Award, Partners in Courage Benefiting the American Cancer Society
1997 Faculty Excellence Award, UT M. D. Anderson Cancer Center
1996 Distinguished Service Award, Houston Chapter of the 100 Black Men Male Call Celebrity Prostate Cancer Fund-Raiser
1995 Runner-Up, Society of Basic Urologic Research Essay Contest
1991 Scholar, American Foundation of Urologic Diseases Scholar
1991 Vernie Stembridge Pathology Award, The UT Southwestern Medical Center
1983 Department of Urology Award, UT M. D. Anderson Cancer Center
1983 Honors Graduate, Temple University School of Medicine
1983 I.A. Burnett Award, The Department of Urology Award
1983 Merit Scholar, Henry J. Kaiser Family Foundation Merit Scholar

Selected Publications

Peer-Reviewed Original Research Articles

1. Sterba KR, Swartz RJ, Basen-Engquist K, Black PC, Pettaway CA. Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial. Support Care Cancer 19(8):1117-24, 8/2011. e-Pub 5/25/2010. PMID: 20499107.
2. Song R, Harris LD, Pettaway CA. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway. Prostate 70(6):571-83, 5/2010. PMID: 19938012.
3. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192-202, 4/1/2010. PMID: 20357281.
4. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic Classification. Eur Urol. e-Pub 10/17/2009. PMID: 19853370.
5. Davis JW, Kamat A, Munsell M, Pettaway C, Pisters L, Matin S. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized? BJU Int. e-Pub 10/2009. PMID: 19874300.
6. Parker PA, Pettaway CA, Babaian RJ, Pisters LL, Miles B, Fortier A, Wei Q, Carr DD, Cohen L. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 27(19):3169-76, 7/1/2009. e-Pub 4/6/2009. PMCID: PMC2716938.
7. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 55(5):1135-43, 5/2009. e-Pub 9/2008. PMID: 18783876.
8. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 3/2009. e-Pub 2/2009. PMCID: PMC2734116.
9. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2/2009. e-Pub 2/2009. PMCID: PMC2650334.
10. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 181(1):81-7; discussion 87, 1/2009. e-Pub 11/13/2008. PMID: 19012911.
11. Svatek RS, Munsell M, Kincaid JM, Hegarty P, Slaton JW, Busby JE, Gaston KE, Spiess PE, Pagliaro LC, Tamboli P, Pettaway CA. Association between lymph node density and disease specific survival in patients with penile cancer. J Urol 182(6):2721-7, 2009. PMID: 19837433.
12. Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway CA, Vijayakumar S, Weinrich S, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD, Kittles RA. Association of HPC2/ELAC2 and RNASEL Non-Synonymous Variants With Prostate Cancer Risk in African American Familial and Sporadic Cases. Prostate 68(16):1790-1797, 12/1/2008. PMID: 18767027.
13. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant Transformation of Testicular Teratoma: A chemoresistant Phenotype. Urol Oncol 26(6):595-9, Nov-Dec, 11/2008. e-Pub 1/2008. PMID: 18367105.
14. Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P. The ratio of matrix metalloproteinase to e-cadherin expression level: prognostic significance of mRNA and protein expression among African American prostate cancer patients. The Prostate 68(13):1467-1476, 9/2008.
15. Strom SS, Yamamura Y, Forman MR, Pettaway CA, Barrera SL, DiGiovanni J. Saturated Fat Intake Predicts Biochemical Failure after Prostatectomy. Int J Cancer 122(11):2581-2585, 6/1/2008. PMID: 18324626.
16. Strom SS, Yamamura Y, Flores-Sandoval FN, Pettaway CA, Lopez DS. Prostate Cancer in Mexican-Americans: Identification of Risk Factors. Prostate 68(5):563-570, 4/2008. PMID: 18247399.
17. Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS. Clinical model of cost of bladder cancer in the elderly. Urology 71(3):519-25, 3/2008. PMID: 18342201.
18. Cárdenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. Gender and Age Differences in Blood Utilization and Length of Stay in Radical Cystectomy: A Population-based Study. Int Urol Nephrol 40(4):893-9, 2008. e-Pub 3/2008. PMID: 18317944.
19. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, Do KA, Davuluri R, Tannir NM. Treatment outcomes of small cell carcinoma of the prostate: A single-center study. Cancer 110(8):1729-1737, 10/15/2007. PMID: 17786954.
20. Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB. Organ Preservation for Muscle-invasive Bladder Cancer by Transurethral Resection. Urology 70(3):473-476, 9/2007. PMID: 17905099.
21. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of Clinical Grade to Predict Final Pathologic Stage in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Therapy. Urology 70(2):252-256, 8/2007. PMCID: PMC2034451.
22. Weinrich S, Vijayakumar S, Powell IJ, Priest J, Hamner CA, McCloud L, Pettaway C. Knowledge of Hereditary Prostate Cancer among HIgh-Risk African American Men. Oncol Nurs Forum 34(4)(4):854-60, 7/2007. PMID: 17723986.
23. De E, Pisters LL, Pettaway CA, Scott S, Westney OL. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient-reported continence outcomes at 32 months. J Urol 177(6)(6):2200-04, 6/2007. PMID: 17509319.
24. Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 177(4)(4):1335-38, 4/2007. PMID: 17382727.
25. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13(4)(4):1224-1231, 2/15/2007. PMID: 17317833.
26. Carmack Taylor CL, de Moor C, Basen-Engquist K, Smith MA, Dunn AL, Badr H, Pettaway C, Gritz ER. Moderator analyses of participants in the Active for Life after Cancer trial: implications for physical activity group intervention studies. Ann Behav Med 33(1)(1):99-104, 2/2007. PMID: 17291175.
27. Baffoe-Bonnie AB, Kittles RA, Gillanders E, Ou L, George A, Robbins C, Ahaghotu C, Bennett J, Boykin W, Hoke G, Mason T, Pettaway C, Vijayakumar S, Weinrich S, Jones MP, Gildea D, Riedesel E, Albertus J, Moses T, Lockwood E, Klaric M, Faruque M, Royal C, Trent JM, Berg K, Collins FS, Furbert-Harris PM, Bailey-Wilson JE, Dunston GM, Powell I, Carpten JD. Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer Study (AAHPC). Prostate 67(1)(1):22-31, 1/1/2007. PMID: 17031815.
28. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate Cancer Progression in the Presence of Undetectable or Low Serum Prostate-Specific Antigen Level. Cancer 109(2)(2):198-204, 1/15/2007. PMID: 17171704.
29. Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Pettaway CA. Randomized prospective trial evaluating testosterone, hemoglobin kinetics, and quality of life during and after 12 months of post-prostatectomy androgen deprivation. Results from the Postoperative Adjuvant Androgen Deprivation (PAAD) Trial. BJU 100(1):63-69, 2007.
30. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 98(6):1176-80, 12/2006. PMID: 17125474.
31. Carmack Taylor CL, Demoor C, Smith MA, Dunn AL, Basen-Engquist K, Nielsen I, Pettaway C, Sellin R, Massey P, Gritz ER. Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psychooncology 15(10):847-62, 10/2006. PMID: 16447306.
32. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176(4 Pt 1):1463-7, 10/2006. PMID: 16952661.
33. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer 107(1):75-82, 7/1/2006. PMID: 16736511.
34. Cárdenas-Turanzas M, Cooksley C, Pettaway CA, Sabichi A, Grossman HB, Elting L. Comparative outcomes of bladder cancer. Obstet Gynecol 108(1):169-75, 7/2006. PMID: 16816072.
35. Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P, Pettaway C, Vijayakumar S, Bennett J, Hoke G, Mason T, Weinrich S, Trent JM, Collins FS, Mousses S, Bailey-Wilson J, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43(6)(6):507-511, 6/2006. e-Pub 9/9/2005. PMCID: PMC2564535.
36. Anai S, Pendleton J, Wludyka P, Williams C, Nelms L, Pettaway C, Rosser CJ. Prostate cancer screening and detection in inner-city and underserved men. J Natl Med Assoc 98(4)(4):515-19, 4/2006. PMCID: PMC2569232.
37. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312(5):584-93, 3/2006. PMID: 16445911.
38. Weinrich S, Weinrich M, Pettaway CA, Vijayakumar S, Powell IJ, Bennett JK, Ahaghotu CA, Hoke G, Mason T, Boykin WH, Priest J, Roberson-Smith, Frost J, Meegan C, Johnson E, Faison-Smith L, Atkinson C, Robertson T, Smith S, Mejia R, Royal C, Mensah E, Kittles R, Trent J, Carpten J, Berg K, Bailey-Wilson J, Baffoe-Bonnie A, Collins F, Dunston G. Prostate Cancer Screening in High Risk Men. Cancer 106(4):796-803, 2006.
39. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-90, 12/2005. PMID: 16280761.
40. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11(19 Pt 1):6889-94, 10/1/2005. PMID: 16203779.
41. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, Saldin K, Dinney CP. Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer 104(5):975-84, 9/1/2005. PMID: 16044400.
42. Eltin LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EBC, Saldin K, Dinney CPN. Correlation between annual volume of cystectomy, professional staffing, and outcomes. Cancer 104(5):975-84, 9/2005.
43. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 14(7):1697-702, 7/2005. PMID: 16030104.
44. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 11(12):4512-20, 6/15/2005. PMID: 15958637.
45. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64(1):40-9, 6/15/2005. PMID: 15651067.
46. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol 173(6):1958-65, 6/2005. PMID: 15879790.
47. Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62(1):101-4, 1/1/2005. PMID: 15389800.
48. Wyatt RB, Sánchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc 96(12):1587-93, 12/2004. PMCID: PMC2568655.
49. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60(4):343-51, 9/1/2004. PMID: 15264247.
50. Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96(7):939-944, 7/2004. PMCID: PMC2568437.
51. Nakamori M, Fu X, Pettaway CA, Zhang X. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 60(1):53-60, 6/15/2004. PMID: 15129429.
52. Carmack Taylor CL, Smith MA, de Moor C, Dunn AL, Pettaway C, Sellin R, Charnsangavej C, Hansen MC, Gritz ER. Quality of life intervention for prostate cancer patients: design and baseline characteristics of the active for life after cancer trial. Control Clin Trials 25(3):265-285, 6/2004. PMID: 15157729.
53. Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate 59(2):167-76, 5/1/2004. PMID: 15042617.
54. Kamat AM, Plager C, Tamboli P, Tran N, Pettaway CA. Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha. J Urol 171(5):1886-7, 5/2004. PMID: 15076299.
55. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587-93, 4/15/2004. PMID: 15102659.
56. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2 alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res 64(2):631-638, 1/15/2004. PMID: 14744778.
57. Ahaghotu C, Baffoe-Bonnie A, Kittles R, Pettaway C, Powell I, Royal C, Wang H, Vijayakumar S, Bennett J, Hoke G, Mason T, Bailey-Wilson J, Boykin W, Berg K, Carpten J, Weinrich S, Trent J, Dunston G, Collins F. Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. Prostate Cancer Prostatic Dis 7(2):165-9, 2004. PMID: 15175665.
58. Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170(5):1856-9, 11/2003. PMID: 14532792.
59. Sánchez-Ortiz RF, Pettaway CA. Natural history, management, and surveillance of recurrent squamous cell penile carcinoma: a risk-based approach. Urol Clin North Am 30(4):853-67, 11/2003. PMID: 14680320.
60. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5):1868-71, 11/2003. PMID: 14532795.
61. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2(9):835-843, 9/2003. PMID: 14555702.
62. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169(6):2113-7, 6/2003. PMID: 12771730.
63. Kuniyasu H, Ukai R, Johnston D, Troncoso P, Fidler IJ, Pettaway CA. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 9(6):2185-94, 6/2003. PMID: 12796385.
64. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8(8):2714-24, 8/2002. PMID: 12171905.
65. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 5/15/2002. PMID: 12173328.
66. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8(5):1253-1265, 5/2002. PMID: 12006546.
67. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol 167(4):1638-42, 4/2002. PMID: 11912379.
68. Weinrich S, Royal C, Pettaway CA, Dunston G, Faison-Smith L, Priest JH, Roberson-Smith P, Frost J, Jenkins J, Brooks KA, Powell I. Interest in genetic prostate cancer susceptibility testing among african American men. Cancer Nurs 25(1):28-34, 2/2002. PMID: 11838717.
69. Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F. African-American Heredity Prostate Cancer Study: A Model for Genetic Research. J Natl Med Assoc 93(4):25S-28S, 12/2001. PMCID: PMC2719991.
70. Giesler EJ, Gee JR, Reece GP, Pettaway CA, Pollock RE, Pisters LL. Cutaneous metastases of penile squamous cell carcinoma following en bloc resection of inguinal recurrence with immediate pedicle flap reconstruction. J Urol 166(4):1384-5, 10/2001. PMID: 11547082.
71. Kuniyasu H, Yasui W, Pettaway CA, Yano S, Oue N, Tahara E, Fidler IJ. Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. Prostate 49(1):19-29, 9/15/2001. PMID: 11550207.
72. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20(31):4188-97, 7/12/2001. PMID: 11464285.
73. Chu LW, Pettaway CA, Liang JC. Genetic abnormalities specifically associated with varying metastatic potential of prostate cancer cell lines as detected by comparative genomic hybridization. Cancer Genet Cytogenet 127(2):161-7, 6/2001. PMID: 11425457.
74. Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F. African-American Heredity Prostate Cancer Study: A Model for Genetic Research. J Natl Med Assoc 93(4):120-3, 4/2001. PMCID: PMC2593987.
75. Slaton JW, Morgenstern N, Levy DA, Santos MW, Tamboli P, Ro JY, Ayala AG, Pettaway CA. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol 165(4):1138-42, 4/2001. PMID: 11257655.
76. Royal C, Baffoe-Bonnie A, Kittles R, Powell I, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu C, Mason T, Johnson E, Obeikwe M, Simpson C, Mejia R, Boykin W, Roberson P, Frost J, Faison-Smith L, Meegan C, Foster N, Furbert-Harris P, Carpten J, Bailey-Wilson J, Trent J, Berg K, Dunston G, Collins F. Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Ann Epidemiol 10(8 Suppl):S68-77, 11/2000. PMID: 11189095.
77. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6(6):2295-308, 6/2000. PMID: 10873080.
78. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6(5):2104-19, 5/2000. PMID: 10815938.
79. Royal C, Baffoe-Bonnie A, Kittles R, Powell I, Bennett J, Hoka G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghoto C, Mason T, Johnson E, Obeikwe M, Simpson C, Mejia R, Boykin W, Roberson P, Frost J, Faison-Smith L, Meegan C, Foster N, Furbert-Harris P, Carpten J, Bailey-Wilson J, Trent J, Berg K, Dunston G, Collins F. Recruitment experiences in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Annals of Epidemiology 10(8):S68 –77, 2000.
80. Pettaway CA. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc 91(12):653-60, 12/1999. PMCID: PMC2608588.
81. Pisters LL, Pettaway CA, Hossan E, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Logothetis CJ. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis 2(S3):S27, 11/1999. PMID: 12496806.
82. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 5(4):783-9, 4/1999. PMID: 10213213.
83. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D, Fidler IJ. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 59(4):872-879, 2/15/1999. PMID: 10029078.
84. Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, Troncoso P. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol 161(2):509-14, 2/1999. PMID: 9915437.
85. Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol 160(5):1770-4, 11/1998. PMID: 9783949.
86. Zagars GK, Pollack A, Pettaway CA. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys 42(3):517-23, 10/1/1998. PMID: 9806509.
87. Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol 160(2):437-42, 8/1998. PMID: 9679893.
88. Hall MC, Sanders JS, Vuitch F, Ramirez E, Pettaway CA. Deoxyribonucleic acid flow cytometry and traditional pathologic variables in invasive penile carcinoma: assessment of prognostic significance. Urology 52(1):111-6, 7/1998. PMID: 9671880.
89. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol 159(3):792-5, 3/1998. PMID: 9474150.
90. Chen ME, Pisters LL, Malpica A, Pettaway CA, Dinney CP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. J Urol 157(6):2120-3, 6/1997. PMID: 9146596.
91. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD, Fidler IJ. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150(5):1571-82, 5/1997. PMCID: PMC1858224.
92. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, Babaian RJ. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 157(3):921-5, 3/1997. PMID: 9072600.
93. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56(24):5594-9, 12/15/1996. PMID: 8971161.
94. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2(9):1627-36, 9/1996. PMID: 9816342.
95. Pettaway CA, Pisters LL, Dinney CP, Jularbal F, Swanson DA, von Eschenbach AC, Ayala A. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol 154(6):1999-2003, 12/1995. PMID: 7500444.
96. Delworth MG, Nishioka K, Pettaway CA, Gurma M, Killion JJ, von Eschenbach AC, Fidler IJ. Systemic administration of 4-amidinoindanon-1 (2-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncology 6:293-299, 1995.
97. Moraes JR, Pettaway C, Stastny P. Prediction of early kidney transplant rejection by a crossmatch with donor skin. Transplantation 48(6):951-952, 12/1989. PMID: 2688207.
98. Pettaway CA, Ball EJ, Stastny P. Allogeneic lymphocyte stimulation by human spleen. Identification of cells that are very effective for presenting class II HLA antigens. Transplantation 46(6):874-8, 12/1988. PMID: 2974656.
99. Pettaway CA, Freeman C, Helderman JH, Stastny P. Kidney transplant recipients with long incubation-positive antiglobulin-negative T cell crossmatches. Transplantation 44(4):529-33, 10/1987. PMID: 3313840.

Invited Articles

1. Velazquez EF, Amin MB, Epstein JI, Grignon DJ, Humphrey PA, Pettaway CA, Renshaw AA, Reuter VE, Srigley JR, Cubilla AL. Protocol for the examination of specimens from patients with carcinoma of the penis. Arch Pathol Lab Med 134(6):923-9, 6/2010. PMID: 20524869.
2. Busby JE, Pettaway CA. What's new in the management of penile cancer? Curr Opin Urol 15(5):350-7, 9/2005. PMID: 16093861.
3. Izawa J, Kedar D, Wong F, Pettaway CA. Sentinel lymph node biopsy in penile cancer: evolution and insights. Can J Urol 12 Suppl 1:24-9, 2/2005. PMID: 15780161.
4. Sánchez-Ortiz RF, Pettaway CA. The role of lymphadenectomy in penile cancer. Urol Oncol 22(3):236-44; discussion 244-5, May-Jun, 5/2004. PMID: 15271324.
5. Pettaway, CA, Lynch D. Contemporary Surgical Management of the Inguinal Region. AUA Update Series Lesson 33(XXI), 2002.
6. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18(5):1050-7, 3/2000. PMID: 10694556.
7. Pettaway CA. Prognostic markers in clinically localized prostate cancer. Tech Urol 4(1):35-42, 3/1998. PMID: 9568775.


1. Pettaway CA. Editorial Comment: The management debate continues! Can J Urol 16(6):4899, 12/2009. PMID: 20003663.
2. Pettaway CA, Horenblas S. Penile Cancer: Incremental Insights into Etiology, Diagnosis, Staging and Management. World J Urol 27(2):139, 4/2009. PMID: 19142645.
3. Pettaway CA. Editorial Comment: The isolated gamma probe technique for sentinel node penile carcinoma detection is unreliable. International Brazilian Journal of Urology 33(1):58-67, 2007.
4. Pettaway CA. Editorial Comment: E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes. Journal of Urology 176(4):1409-1414, 2006.
5. Pettaway CA. Editorial Comment: Penile carcinoma. Is ND: YAG Laser therapy radical enough? Journal of Urology 168:2421, 2002.
6. Pettaway CA. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3. Journal of Urology 159:2035-40, 1998.

Book Chapters

1. Pettaway CA, Lynch DF, Davis JW. Tumors of the Penis. In: Campbell's Urology, 9th. Ed(s) LR Kavoussi, AC Novick, AW Partin, CA Peters, AJ Wein. Saunders Elsevier: Philadelphia, 959-992, 2007.
2. Lynch DF, Pettaway CA. Tumors of the Penis. In: Campbell’s Urology, 8th. Ed(s) AB Retik, ED Vaughan Jr., AJ Wein. WB Sanders Co. Philadelphia, 2945-2981, 2002.
3. Corral DA, Pettaway CA. Atlas of Surgical Oncology. In: Contemporary Principles and Practice, Cancer of Penis and Urethra. McGraw-Hill, 791-812, 2001.
4. Pettaway CA, Balbay MD, Grossman HB. Clinical Oncology. In: Penis and Urethra. Bermedica Production, Ltd., 1885-1905, 2000.
5. Pettaway CA Dinney CPN. Urologic and Male Genital Cancer. In: Clinical Oncology. American Cancer Society, 435-454, 2000.
6. Fidler IJ, Kuniyasu H, Greene GF, Troncoso P, Pettaway CA. Molecular diagnosis to predict the metastatic potential of human prostate cancer. In: Progress in Anti-Cancer Chemotherapy. Springer-Verlag, 153-161, 1999.
7. Pettaway CA von Eschenbach AC. Surgery of penile carcinoma. In: Atlas of Surgical Oncology. WB Saunders Co, 615-632, 1995.
8. Stastny P, Nunez G, Pettaway C. Class II major histocompatibility antigens of human monocytes, endothelial cells, and dendritic cells. In: HLA Class II Antigens. Springer-Verlag, 356-373, 1986.

Manuals, Teaching Aids, Other Teaching Publications

1. Hoffman K, Pagliaro L, Pettaway CA. OncoLog, MD Anderson's Report to Physicians, Penile Cancer. 58(7), 4-6, 8,, 7/2013.

Last updated: 1/13/2015